preoperative gemcitabine based chemoradiation therapy for resectable and borderline resectable pancreatic cancer phase1 study
Phase 1
- Conditions
- resectable and borderline resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000020977
- Lead Sponsor
- fukushima medical university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1) unresectable pancreatic cancer 1 distant organ metastasis 2 peritoneal dissamination 3 para aortic lymph node metastasis 4 pancreatic cancer with artery invasion, such as abdominal aorta, superior mesenteric artery, ceriac artery, common hepatic artery, or proper hepatic artery. 5 portal vein invasion beyond reconstruction patient with interstitial lung disease or fibroid lung patient with severe diarrhea active viral infection excluding viral hepatitis patient with double cancer a woman of childbearing potential patient with severe psychological disorder patient with severe allergy to any drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method occurrence of side effect of preoperative gemcitabine based chemoradiation therapy
- Secondary Outcome Measures
Name Time Method postoperative complication, 2-year recurrence-free survival, 2-year overall survival, recurrence site